PLK1 as a potential prognostic marker of gastric cancer through MEK-ERK pathway on PDTX models.

Due to the complexity of its molecular mechanism and the clinical heterogeneity, gastric cancer death rate ranks third and its incidence worldwide has an increasing trend. 1 – 4 Despite the current multimodal therapy for the treatment of gastric cancer, including surgery, radiotherapy and chemotherapy, and targeted therapies, the 5-year survival rate of gastric cancer patients is still low (25%–30%) and the prognosis is poor. 5 – 7 Understanding the underlying molec

also in 63,971 other papers